碘染色缺失与中国食管病变进展的前瞻性内镜监测研究
基于中国人群随机对照试验的6年随访数据,研究碘染色缺失与食管病变进展的关联。在1468名参与者中,开发队列788人,验证队列680人。碘染色缺失但组织学非异型增生的病变中,39.3%进展为重度异型增生、原位癌或食管鳞癌。结合年龄、BMI、病理和碘染色的模型预测进展的AUC在开发集为0.868,验证集为0.850。
要点
- 碘染色缺失但组织学非异型增生的病变有高进展风险,占进展病变的39.3%。
- 基于年龄、BMI、病理和碘染色的模型可准确预测食管病变进展。
- 模型识别的高或中高风险患者纳入监测可几乎避免漏诊。
核心结论
- 基线色素内镜碘染色缺失可高敏感识别有进展风险的食管病变。
- 结合碘染色和其他特征的模型比基线活检组织学分析更准确识别进展风险患者。
研究设计与样本
- 基于中国人群随机对照试验的6年随访数据,纳入1468名45-69岁参与者。
- 开发队列788人接受中位4.2年内镜复查,验证队列680人通过年度入户访谈或电子登记确定结局。
主要发现
- 开发队列中,11个碘染色缺失但组织学非异型增生的病变进展为重度异型增生、原位癌或食管鳞癌,占所有进展病变(n=28)的39.3%。
- 验证队列中,6例碘染色缺失但组织学非异型增生的患者 later诊断为食管鳞癌,占所有进展患者(n=12)的50.0%。
关键数值与推荐
- 模型预测重度异型增生、原位癌或食管鳞癌的AUC在开发集为0.868(95%CI 0.817-0.920),验证集为0.850(95%CI 0.748-0.952)。
- 模型基于患者年龄、体重指数、病理发现和基线碘染色。
临床怎么用
- 在内镜筛查中,对碘染色缺失但组织学非异型增生的患者应警惕进展风险。
- 可使用结合年龄、BMI、病理和碘染色的模型评估进展风险,指导监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chromoendoscopy with iodine staining is used to identify esophageal squamous dysplasia and esophageal squamous cell carcinomas (ESCCs)-absence of staining indicates suspicious regions of dysplasia. However, screening detects precancerous lesions (mild and moderate dysplasia) that do not require immediate treatment; it is a challenge to which lesions are at risk for progression. We investigated the association between absence of iodine staining at chromoendoscopy screening and lesion progression using 6 years of follow-up data from a population-based randomized controlled trial in China. We then constructed and validated a model to calculate risk of progression to severe dysplasia, carcinoma in situ, or ESCC. METHODS: We collected data from 1468 participants (45-69 years old) who were either negative for iodine staining at a baseline chromoendoscopy or found to have mild or moderate dysplasia in histologic analysis of biopsies in the Endoscopic Screening for Esophageal Cancer study in China, from January 2012 through September 2016; 788 of these participants were re-examined by endoscopy after a median interval of 4.2 years (development cohort). We investigated the association between absence of iodine staining and progression of esophageal lesions using Cox prediction models, considering corresponding baseline pathology findings and patient answers to a comprehensive questionnaire. Patients who did not receive a follow-up examination (n = 680) was used as the validation cohort; outcome events in these patients were identified by annual door to door active interviews or linkage with local electronic registry data. The primary outcome was incident esophageal severe dysplasia, carcinoma in situ, or ESCC. RESULTS: In the development cohort, 11 lesions that did not stain with iodine but were classified as not dysplastic in the histology analysis were found to be severe dysplasia, carcinoma in situ, or ESCC at the follow-up evaluation. These lesions accounted for 39.3% of all progressed lesions (n = 28). In the validation cohort, 6 patients with lesions did not stain with iodine but were classified as not dysplastic by histology had a later diagnosis of ESCC, determined from medical records; these patients accounted for 50.0% of all patients with lesion progression (n = 12) until the closing date of this study. We developed a model based on patient age, body mass index, pathology findings, and baseline iodine staining to calculate risk for severe dysplasia, carcinoma in situ, or ESCC. It identified patients for severe dysplasia, carcinoma in situ, or ESCC in the development set with an area under the curve of 0.868 (95% CI, 0.817-0.920) and in the validation set with an area under the curve of 0.850 (95% CI, 0.748-0.952). Almost no cases would be missed if subjects determined to be high or intermediate-high risk subjects by the model were included in surveillance. CONCLUSIONS: Absence of iodine staining at baseline chromoendoscopy identifies esophageal lesions at risk of progression with a high level of sensitivity. A model that combines results of iodine chromoendoscopy with other patient features identifies patients at risk of lesion progression with greater accuracy than histologic analysis of baseline biopsies.
引用
- Liu M, Liu Z, Liu F, et al. Absence of Iodine Staining Associates With Progression of Esophageal Lesions in a Prospective Endoscopic Surveillance Study in China. Clin Gastroenterol Hepatol. 2019. PMID: 31518715. doi:10.1016/j.cgh.2019.08.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。